Literature DB >> 18336459

Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status.

F M E Wagenlehner1, T Diemer, K G Naber, W Weidner.   

Abstract

In only approximately 10% of men with symptoms of chronic prostatitis/chronic pelvic pain syndrome bacterial infection of the prostate can be demonstrated by the Meares and Stamey 4-glass or the pre- and post-prostate massage (PPM) two-glass test. Chronic bacterial prostatitis is mainly caused by Gram-negative uropathogens. The role of Gram-positives, atypicals and anaerobes is still debatable. For treatment, fluoroquinolones are considered the drugs of choice because of their favourable pharmacokinetic properties and their antimicrobial spectrum. As relapse and re-infection are a major problem in chronic bacterial prostatitis, only the results of studies with a follow up period of at least 6 months are meaningful. Analysing the concentrations of various fluoroquinolones in prostatic and seminal fluid as well as in prostatic tissue, it becomes, however, obvious that fluoroquinolones differ not only in plasma concentrations, but also in their penetration ability to these sites. Nevertheless, the concentrations at the site of infection of most fluoroquinolones with this indication should be sufficient for the treatment of chronic bacterial prostatitis caused by susceptible pathogens. On the other hand, male accessory gland infection has been linked to male infertility. However, there is still a lack of evidence showing that bacterial prostatitis would have a negative impact on sperm quality.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18336459     DOI: 10.1111/j.1439-0272.2007.00827.x

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  9 in total

Review 1.  Therapeutic roles of curcumin: lessons learned from clinical trials.

Authors:  Subash C Gupta; Sridevi Patchva; Bharat B Aggarwal
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

2.  Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis.

Authors:  Tommaso Cai; Sandra Mazzoli; Francesca Meacci; Vieri Boddi; Nicola Mondaini; Gianni Malossini; Riccardo Bartoletti
Journal:  J Microbiol       Date:  2011-06-30       Impact factor: 3.422

Review 3.  [Male adnexitis].

Authors:  T Diemer; O Gralla
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

4.  Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis--case report.

Authors:  S Letkiewicz; R Miedzybrodzki; W Fortuna; B Weber-Dabrowska; A Górski
Journal:  Folia Microbiol (Praha)       Date:  2009-11-24       Impact factor: 2.099

5.  Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis.

Authors:  Wei-Ping Zhao; Yong-Tao Li; Jun Chen; Zhi-Gen Zhang; Hai Jiang; Dan Xia; Shuo Wang; Ping Wang
Journal:  Asian J Androl       Date:  2012-07-16       Impact factor: 3.285

6.  The effect of chronic bacterial prostatitis on semen quality in adult men: a meta-analysis of case-control studies.

Authors:  Yonggang Shang; Chengcheng Liu; Dong Cui; Guangwei Han; Shanhong Yi
Journal:  Sci Rep       Date:  2014-11-28       Impact factor: 4.379

Review 7.  Bacterial Biofilm and its Role in the Pathogenesis of Disease.

Authors:  Lene K Vestby; Torstein Grønseth; Roger Simm; Live L Nesse
Journal:  Antibiotics (Basel)       Date:  2020-02-03

8.  GPs' attitudes towards the diagnosis and treatment of male urinary tract infections: a qualitative interview study in Ireland.

Authors:  Róisín Fallon; Karen Farrell; Genevieve Leon; Aparna Rajan; Sinead Duane; Christine FitzGerald; Marie Tierney; Akke Vellinga
Journal:  BJGP Open       Date:  2019-10-15

9.  Investigating Causal Relations between Genetic-Related Intermediate Endophenotype and Risk of Chronic Prostatitis: Mendelian Randomization Study.

Authors:  Shengfeng Zhang; Xing Xie; Lei Yu; Nili Jiang; Xihuan Wei; Yanling Hu
Journal:  Oxid Med Cell Longev       Date:  2022-08-28       Impact factor: 7.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.